Trials / Conditions / Myelodysplastic Syndrome With Excess Blasts-2

Myelodysplastic Syndrome With Excess Blasts-2

10 registered clinical trials studyying Myelodysplastic Syndrome With Excess Blasts-2 — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning NCT06247917	Ruijin Hospital	Phase 2
Recruiting	BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT05703542	Eric Stephen Winer, MD	Phase 1
Terminated	CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measur NCT04526288	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by NCT04027309	Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 3
Recruiting	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43 NCT03850574	Aptose Biosciences Inc.	Phase 1 / Phase 2
Active Not Recruiting	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed NCT03839771	Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 3
Active Not Recruiting	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034	M.D. Anderson Cancer Center	Phase 1
Completed	Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grad NCT02756572	University of Washington	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740	Fred Hutchinson Cancer Center	Phase 2